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OBJECTIVES We sought to evaluate the response to antiplatelet therapy in patients with stent thrombosis
(ST).
BACKGROUND Stent thrombosis is associated with considerable morbidity and mortality. An impaired
response to antiplatelet therapy might be related to an increased risk for ST.
METHODS Eighty-two patients were included in the present study: 23 patients with previous ST, 50
matched controls (coronary stenting without ST), and 9 healthy volunteers. Platelet
aggregation (PA) was studied (optical aggregometry) under monotherapy with acetylsalicylic
acid (ASA) 100 mg daily for one month, followed by dual therapy with ASA 100 mg and
clopidogrel 75 mg daily (loading dose 300 mg) for another month.
RESULTS Maximal (5 and 20 mol) adenosine diphosphate-induced PA was significantly higher in
patients with ST compared with controls (5 mol, p  0.005; 20 mol, p  0.05) and
volunteers (5 mol, p  0.005; 20 mol, p  0.05). Resistance to ASA (20% aggregation
with 0.5 mg/ml arachidonic acid) was more prevalent in patients with ST (48%) compared
with control patients (32%, p  ns) and volunteers (0%, p  0.01). Clopidogrel significantly
reduced PA in all three groups, but intergroup differences persisted. Clopidogrel resistance
(10% relative change) was similar in patients with ST, control patients, and volunteers (4%,
6%, and 11%, respectively, all p  NS). However, combined ASA and clopidogrel resistance
was more prevalent in patients with ST (52%) compared with controls (38%, p  NS) and
volunteers (11%, p  0.05).
CONCLUSIONS Patients with previous ST show an impaired response to antiplatelet therapy with ASA
compared with controls and volunteers. Additional treatment with clopidogrel is not able to
overcome these differences in PA. Acetylsalicylic acid but not clopidogrel resistance appears
to be associated with ST. (J Am Coll Cardiol 2005;45:1748–52) © 2005 by the American
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.01.058College of Cardiology Foundation
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dtent thrombosis (ST) remains a serious complication of
oronary artery stent implantation. Despite routine dual
ntiplatelet therapy with acetylsalicylic acid (ASA) and
hienopyridines (1), the incidence of ST persists at a rate of
.5% to 2 % (2,3). Several factors have been associated with
See page 1757
n increased risk of ST: long and multiple stents (2,3), stent
alapposition (4), residual dissection (2), and platelet poly-
orphism (5). Resistance to ASA and clopidogrel has been
uggested as a possible cause of ST, but conclusive data are
acking (6–9). Thus, the purpose of the present study was to
valuate the response to antiplatelet therapy in patients with
revious ST and to compare it with a control group of
atients without ST and healthy volunteers.
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atient population. Between 1995 and 2003, 6,058 pa-
ients underwent bare-metal coronary stent implantation
t our institution. Ninety-five patients suffered angio-
raphically verified subacute (median seven days after im-
lantation) ST during long-term follow-up. Of these
atients, 12 (13%) died, 60 (63%) refused or had contrain-
ications to study inclusion, and 23 (24%) agreed to
articipate. Fifty patients undergoing stent implantation
ollowed by dual antiplatelet therapy for 1 to 12 months
ithout ST during follow-up served as controls, and nine
ealthy volunteers served as a reference group. Control
atients were matched with respect to age, gender, risk
actors, and angiographic characteristics to exclude con-
ounding factors (Table 1).
Exclusion criteria were acute coronary syndrome in the
ast six months, known allergy to ASA or clopidogrel,
ndication for long-term treatment with clopidogrel or other
ntiplatelet therapy except ASA, recent gastrointestinal
leeding, pregnancy, known platelet dysfunction, bleeding
isorder, or abnormal platelet count (100,000/mm3). The
ean time between stent implantation and study entry was
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June 7, 2005:1748–52 Platelet Aggregation and Stent Thrombosist least six months (64  19 months for patients with ST;
1  24 months for control patients, p  0.001).
tudy protocol. The local ethics committee approved the
rotocol, and all patients gave written informed consent. To
inimize potential drug interactions, statins were discon-
inued during the study period. However, it was felt
nethical to discontinue other cardiovascular medications,
uch as beta-blockers, angiotensin-converting enzyme in-
ibitors, and calcium antagonists. First, platelet aggregation
PA) was assessed after an interval of four weeks under
onotherapy with ASA 100 mg daily (any other antiplatelet
edication was not permitted). Then, all patients received
ual therapy with clopidogrel (300 mg loading dose, fol-
owed by 75 mg daily) in addition to ASA. A second PA
as performed after a mean of 31  4 days under combi-
ation therapy.
Abbreviations and Acronyms
ADP  adenosine diphosphate
ASA  acetylsalicylic acid
ARA  arachidonic acid
PA  platelet aggregation
ST  stent thrombosis
able 1. Baseline Demographics and Angiographic
haracteristics
Patients
With ST
(n  23)
Control
Patients
(n  50) p Value
ge, mean  SD 64  12 66  4 NS
emale gender, % 30 17 NS
ypertension, % 39 40 NS
amily history, % 26 34 NS
urrent smoking, % 30 45 NS
yslipidemia, % 74 64 NS
iabetes, % 14 14 NS
revious CABG, % 5 9 NS
ultivessel disease, % 17 28 NS
V ejection fraction, %
Before ST 56  15 65  12 0.05
After ST 49  14
tent length, mm  SD 15  9 15  7 NS
tent diameter, mm  SD 2.9  0.2 3.1  0.3  0.05
nflation pressure, bar  SD 13  5 13  3 NS
esidual dissection, % 5 0 NS
reated vessel, % NS
LAD 61 51
LCX 17 15
RCA 22 34
eta-blocker, % 65 51 NS
alcium antagonist, % 0 13 NS
CE inhibitor, % 52 21  0.05
T-1 receptor antagonist, % 35 17  0.05
itrates, % 17 9 NS
iuretics, % 55 15  0.05
edication at time of PA assessment.
ACE  angiotensin-converting enzyme; AT-1  angiotensin 1; CABG 
oronary artery bypass grafting; LAD  left anterior descending; LCX  leftA
ircumflex artery; NS  not significant; PA  platelet aggregation; RCA  right
oronary artery; ST  stent thrombosis.aboratory determinations. We determined PA using a
our-channel light transmission aggregometer (APACT,
ndotell AG, Allschwil, Switzerland). The technology has
een described in detail previously (10). Platelet activation
as achieved with low and high concentrations of adenosine
iphosphate (ADP) (5 and 20 mol). Activation by arachi-
onic acid (ARA) (0.5 mg/ml) was used to assess ASA
esistance.
rug resistance. According to previous publications, the
ollowing definitions were used.
Aspirin resistance:
. ARA (0.5 mg/ml)-induced maximal PA: 20% (6,11),
or
. ADP (5 mol/l)-induced maximal PA: 70% (11), or
. ADP (20 mol/l)-induced maximal PA: 70% (11).
Clopidogrel resistance (5 and 20 mol/l ADP-induced
A) adapted from Gurbel et al. (12):
. Normal response: relative change () between aggrega-
tion under ASA and ASA plus clopidogrel 30%
. Low response:   10% to 29%
. No response:  10%.
tatistical analysis. Continuous data were expressed as
ean  standard deviation. Wilcoxon rank sum test was
sed for intergroup comparison between patients with ST
nd control patients (Table 1). Comparison between cate-
orical data was performed using the chi-square test. A
aired t test served as method to compare intragroup
ontinuous variables (Fig. 1). A one-way analysis of variance
as used to assess differences of continuous values between
he three different groups (Fig. 1). A two-sided p value of
0.05 was considered significant. All statistical analyses
ere performed with SPSS 10.0.5 software (SPSS Institute,
hicago, Illinois).
ESULTS
aseline characteristics of patients with ST and control
atients are shown in Table 1. Systolic left ventricular
unction was somewhat reduced in patients with ST as the
esult of ST-induced myocardial infarction. Therefore,
ore patients with ST were treated with angiotensin-
onverting enzyme inhibitors or angiotensin-1 receptor
ntagonists.
DP-induced PA. 5 mol of ADP-induced aggregation
nder monotherapy with ASA was significantly blunted in
atients with ST compared with control patients (p 
.005) and volunteers (p  0.005) (Fig. 1). There were no
ifferences between control patients and volunteers. Clopi-
ogrel significantly decreased maximal aggregation in each
roup (ST patients: from 63.9  10% to 40.0  10%;
ontrols: from 53.4  10% to 30.8  10%; volunteers: from
4.8  9% to 24.8  8%; all p  0.005) but was not able
o overcome baseline differences under monotherapy with
SA. 20 mol ADP-induced PA revealed comparable
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0.5 mg/ml arachionic acid) on ASA (100 mg daily) in patients with ST, control
patients, and volunteers.
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evel (Pearson correlation coefficient r  0.7). Differences
etween groups remained similar (Fig. 1).
rachidonic acid-induced PA. Aggregation with ARA
as highest in patients with ST (23.7  18%) followed by
ontrol patients (18.0 12%, p ns) and volunteers (8.7
%, p  0.005 vs. patients with ST). Values remained
nchanged under dual therapy with ASA and clopidogrel
ST patients: 19.5  11%; controls 17.1  13%; volunteers
1.1  4%).
esistance to ASA or clopidogrel. The ASA resistance
as highest in ST patients using one of the following
efinitions:
. ARA: see the upper panel of Figure 2
. 5 mol ADP: ST patients 26%, controls 6%, volunteers
0% (p  0.06 for ST patients vs. volunteers)
. 20 mol ADP: ST patients 78%, controls 53%, volun-
teers 44% (p  0.05 for ST patients vs. controls or
volunteers).
Clopidogrel resistance occurred with similar frequency in
ll groups (Fig. 2, middle panel). Low response was more
requent in patients with ST, but there were no significant
ifferences among groups:
. 5 mol ADP: ST patients 30%, controls 19%, volun-
teers 11% (all p  NS)
. 20 mol ADP: ST patients 39%, controls 28%, volun-
teers 33% (all p  NS).
Combined ASA and clopidogrel resistance was most
requent in patients with ST, reflecting the high incidence
f abnormal response to either ASA or clopidogrel:
. ARA (for ASA resistance) and 5 mol ADP (for
clopidogrel resistance or low response): ST patients
70%, controls 53%, volunteers 22% (p  0.05 for
patients with ST vs. volunteers)
. ARA (for ASA resistance) and 5 mol ADP (for
clopidogrel resistance) (Fig. 2, bottom panel).
ISCUSSION
he present study evaluated the relation between ST and
A. The principal finding was a significantly higher aggre-
ation level in patients with ST compared with control
atients and volunteers. The addition of clopidogrel to ASA
id not overcome this difference but reduced the aggrega-
ion level in all groups to a similar extent (Fig. 1). Similarly,
he incidence of ASA resistance was consistently higher in
atients with ST compared with control patients and
olunteers. Previous studies identified ASA resistance as a
trong predictor for cardiovascular events during follow-up
6). Failure of ASA to protect against cardiovascular events
as been attributed to poor compliance, drug interactions,
lternative pathways of platelet activation (13,14), and
enetic polymorphisms (15). Poor compliance to drugigure 1. Platelet aggregation (top: 5 mol adenosine diphosphate [ADP];
iddle: 20 mol ADP) in patients with stent thrombosis (ST), control patients,
nd volunteers. Black boxes  acetylsalicyclic acid (ASA) (100 mg daily) alone;
hite boxesASA plus clopidogrel (75 mg daily). Platelet aggregation (bottom:ntake does not apply to our study because patients were
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June 7, 2005:1748–52 Platelet Aggregation and Stent Thrombosisonitored for drug intake and because aggregation values
nder ARA remained constant over time. Drug interactions
ave been minimized by excluding drugs other than pre-
cribed by the protocol. Thus, alternative pathways of
latelet activation and genetic polymorphisms appear
esponsible for the phenomenon of ASA resistance, and
creening tests could be envisioned in patients undergo-
ng coronary stent implantation to identify those at risk
or ST. Clopidogrel showed a comparable inhibitory
ffect in all three groups. The incidence of clopidogrel
esistance (i.e., the inability to further reduce PA by
29% beyond ASA alone) was generally low, but as
any as 39% of patients showed a low response to this
rug. These data are in line with previous reports (12),
lthough the definition of clopidogrel resistance may vary
mong different studies.
Another important finding of the present study was the
nability of clopidogrel to overcome the impaired response
o ASA in ST patients because the level of ADP-induced
ggregation remained higher in this group. Higher clopi-
ogrel doses (e.g., loading 600 mg, 150 mg daily) may have
mproved the low response to this drug (8). Notwithstand-
ng, the causes for ST are multifaceted, but ASA resistance
ay play a key role among other factors.
tudy limitations. This is a retrospective case-control
tudy, with its inherent shortcomings. The number of
atients studied limits the power to detect clinically impor-
ant differences in prevalence of resistance between groups.
n addition, only a limited number of patients with ST were
tudied. Many of them refused to participate because of fear
f ST recurrence. Finally, urine metabolites of thromobox-
ne were not measured.
onclusions. The phenomenon of resistance to ASA and
he combination of ASA and clopidogrel may play an
mportant role in the pathophysiology of ST. In the future,
imple and reliable tests to assess for these resistances are
arranted to prevent atherothrombotic events and their
equelae.
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